247 related articles for article (PubMed ID: 31369199)
1. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab.
Focosi D; Tuccori M; Maggi F
Rev Med Virol; 2019 Nov; 29(6):e2077. PubMed ID: 31369199
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
Sharma K; Tolaymat S; Yu H; Elkhooly M; Jaiswal S; Jena A; Kakara M; Sriwastava S
J Neurol Sci; 2022 Dec; 443():120459. PubMed ID: 36283150
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions.
Bennett CL; Focosi D; Socal MP; Bian JC; Nabhan C; Hrushesky WJ; Bennett AC; Schoen MW; Berger JR; Armitage JO;
Lancet Haematol; 2021 Aug; 8(8):e593-e604. PubMed ID: 34329579
[TBL] [Abstract][Full Text] [Related]
4. Brain Lesion in the Setting of Chronic Rituximab Treatment.
Yazdani M; Antonucci M; Spampinato MV
JAMA Oncol; 2020 Jul; 6(7):1093-1094. PubMed ID: 32463440
[No Abstract] [Full Text] [Related]
5. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments.
Clavel G; Moulignier A; Semerano L
Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224
[TBL] [Abstract][Full Text] [Related]
6. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
Berger JR; Malik V; Lacey S; Brunetta P; Lehane PB
J Neurovirol; 2018 Jun; 24(3):323-331. PubMed ID: 29508305
[TBL] [Abstract][Full Text] [Related]
7. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
Baber U; Bouley A; Egnor E; Sloane JA
J Neurol; 2018 Oct; 265(10):2342-2345. PubMed ID: 30109480
[TBL] [Abstract][Full Text] [Related]
8. Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies.
Hadjadj J; Guffroy A; Delavaud C; Taieb G; Meyts I; Fresard A; Streichenberger N; L'Honneur AS; Rozenberg F; D'Aveni M; Aguilar C; Rosain J; Picard C; Mahlaoui N; Lecuit M; Hermine O; Lortholary O; Suarez F
J Clin Immunol; 2019 Jan; 39(1):55-64. PubMed ID: 30552536
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy and newer biological agents.
Berger JR
Drug Saf; 2010 Nov; 33(11):969-83. PubMed ID: 20925435
[TBL] [Abstract][Full Text] [Related]
10. Progressive multifocal leukoencephalopathy in autoimmune diseases.
Palazzo E; Yahia SA
Joint Bone Spine; 2012 Jul; 79(4):351-5. PubMed ID: 22281228
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-associated progressive multifocal leukoencephalopathy.
Sokol J; Lisá L; Zeleňáková J; Balhárek T; Plameňová I; Staško J; Kubisz P
Vnitr Lek; 2017; 63(1):60-64. PubMed ID: 28225293
[TBL] [Abstract][Full Text] [Related]
12. An autopsy case of progressive multifocal leukoencephalopathy after rituximab therapy for malignant lymphoma.
Muto R; Sugita Y; Momosaki S; Ito Y; Wakugawa Y; Ohshima K
Neuropathology; 2019 Feb; 39(1):58-63. PubMed ID: 30511425
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus.
Kapoor T; Mahadeshwar P; Hui-Yuen J; Quinnies K; Tatonetti N; Gartshteyn Y; Guo C; Geraldino-Pardilla L; Askanase AD
Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32513809
[TBL] [Abstract][Full Text] [Related]
14. AIDS-associated progressive multifocal leukoencephalopathy : current management strategies.
Roberts MT
CNS Drugs; 2005; 19(8):671-82. PubMed ID: 16097849
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.
Major EO
Annu Rev Med; 2010; 61():35-47. PubMed ID: 19719397
[TBL] [Abstract][Full Text] [Related]
16. JC polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen-sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Toyoda M; Thomas D; Ahn G; Kahwaji J; Mirocha J; Chu M; Vo A; Suviolahti E; Ge S; Jordan SC
Transpl Infect Dis; 2015 Dec; 17(6):838-47. PubMed ID: 26437369
[TBL] [Abstract][Full Text] [Related]
17. A rare urinary JC virus reactivation after long-term therapy with rituximab.
Di Maida F; Viola L; Lambertini L; Mari A; Mencarini J; Borchi B; Carini M; Zammarchi L; Minervini A
Int J Infect Dis; 2021 Feb; 103():447-449. PubMed ID: 33278620
[TBL] [Abstract][Full Text] [Related]
18. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
19. The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases.
Toussirot É; Bereau M
Inflamm Allergy Drug Targets; 2014; 13(2):121-7. PubMed ID: 24559124
[TBL] [Abstract][Full Text] [Related]
20. Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab.
Martinot M; Ahle G; Petrosyan I; Martinez C; Gorun DM; Mohseni-Zadeh M; Fafi-Kremer S; Tebacher-Alt M
Emerg Infect Dis; 2018 Aug; 24(8):1594-1596. PubMed ID: 30016251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
